Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Regular Insulin Clear all
Completed Phase 3 Interventional

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

NCT06109311
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Bryant, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 19, 2026, 2:53 AM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Quality Protein for Assisting With Weight Loss

NCT03085511
View directory record Official record
Conditions
Obesity
Interventions
Egg breakfast (EB), Weight Loss Counseling, Weight Loss Diet, Cereal Breakfast (CB)
Behavioral
Lead sponsor
Texas Tech University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Sep 19, 2026, 2:53 AM EDT
Terminated Not applicable Interventional Results available

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

NCT00487162
View directory record Official record
Conditions
Hyperglycemia
Interventions
intensive glycemic control, conventional glycemic control
Procedure · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 95 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 19, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional

Diabetes Body Project 2

NCT07468188
View directory record Official record
Conditions
Eating Disorders, Type 2 Diabetes
Interventions
Body Project Type 2
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

NCT01658579
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Temecula, California • Minneapolis, Minnesota • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2015 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

NCT02706288
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Weight loss with very low fat plant-based diet and regular exercise
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

NCT03922750
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin glargine U100
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Walnut Creek, California • Roswell, Georgia • Idaho Falls, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chromium's Effect on Insulin Resistance in Obesity

NCT00997659
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
chromium picolinate
Dietary Supplement
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

NCT00765817
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
placebo, exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
40
States / cities
Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2016 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

High-fat Meal Challenge in Pediatrics

NCT05230433
View directory record Official record
Conditions
Pediatric Obesity, Insulin Resistance
Interventions
High-fat Challenge
Dietary Supplement
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 19, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

NCT01753674
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
TA-65, Placebo
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
35 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Results available

Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon

NCT02516150
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ethanol, Glucagon
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 3 Interventional

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy

NCT00598793
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, insulin glargine, metformin, pioglitazone
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Concord, California • Los Angeles, California • Walnut Creek, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2017 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement

NCT01794949
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Resolute Integrity stent
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes

NCT00348374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Lispro, Exubera
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
62
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2010 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 4 Interventional Results available

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652
View directory record Official record
Conditions
Hypertension
Interventions
Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 19, 2026, 2:53 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Use of Levemir® Improves Metabolic and Clinical Status in Cystic Fibrosis-related Diabetes (CFRD)

NCT00639626
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes
Interventions
insulin detemir [rDNA origin] injection
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
16 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

NCT04461015
View directory record Official record
Conditions
Healthy
Interventions
0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study
Drug
Lead sponsor
Adrian Vella
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 20, 2022 · Synced Sep 19, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117
View directory record Official record
Conditions
Hypertension
Interventions
Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), Chlorthalidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 19, 2026, 2:53 AM EDT
Terminated Phase 1 Interventional Results available

A Research Trial of Aralast in New Onset Diabetes (RETAIN)

NCT01183468
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Sep 19, 2026, 2:53 AM EDT